Anti-Podoplanin/gp36/PDPN Antibody Picoband®

Overview

Anti-Podoplanin/gp36/PDPN Antibody Picoband® is an antibody targeting PDPN. Common applications include WB, IHC, Flow Cytometry, ELISA. Key specifications include host: Rabbit; clonality: Polyclonal; isotype: Rabbit IgG; reactivity: Mouse,Rat; observed MW: 38 kDa; calculated MW: 17579 MW.

Boster Bio Anti-Podoplanin/gp36/PDPN Antibody catalog # PA1675. Tested in WB applications. This antibody reacts with Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.

Key elements and design rationale

• Target: PDPN — Podoplanin
• Antibody format: Host: Rabbit; Clonality: Polyclonal; Isotype: Rabbit IgG
• Species reactivity: Mouse,Rat
• Molecular weight guidance: Observed: 38 kDa; Calculated: 17579 MW

Specificity note: No cross reactivity with other proteins.

Biological background

Protein function (datasheet): May be involved in cell migration and/or actin cytoskeleton organization. When expressed in keratinocytes, induces changes in cell morphology with transfected cells showing an elongated shape, numerous membrane protrusions, major reorganization of the actin cytoskeleton, increased motility and decreased cell adhesion. Required for normal lung cell proliferation and alveolus formation at birth. Induces platelet aggregation. Does not have any effect on folic acid or amino acid transport. Does not function as a water channel or as a regulator of aquaporin-type water channels (By similarity). .

Scientific background (datasheet): PDPN (Podoplanin), also called T1A, T1A2, GP36, OTS8 or AGGRUS, is a protein that in humans is encoded by the PDPN gene. This gene encodes a type-I integral membrane glycoprotein with diverse distribution in human tissues. The PDPN gene is mapped to chromosome 1 by the International radiation Hybrid mapping consortium. The physiological function of PDPN may be related to its mucin-type character. The specific function of this protein has not been determined but it has been proposed as a marker of lung injury. Immunohistochemical analysis of PDPN in placenta, kidney, lung, and nasal polyps showed expression at the apical plasma membrane of vascular endothelial cells and in alveolar epithelial cells. Overexpression of rat PDPN in human and rodent endothelial cells promoted formation of elongated cell extensions and significantly increased endothelial cell adhesion, migration, and tube formation. Inhibition of PDPN expression by small interfering RNAs decreased cell adhesion in cultured human dermal lymphatic endothelial cells.

Cellular localization (datasheet): Membrane ; Single-pass type I membrane protein . Cell projection, lamellipodium membrane ; Single-pass type I membrane protein . Cell projection, filopodium membrane ; Single-pass type I membrane protein . Cell projection, microvillus membrane ; Single-pass type I membrane protein . Cell projection, ruffle membrane ; Single-pass type I membrane protein . Localized to actin-rich microvilli and plasma membrane projections such as filopodia, lamellipodia and ruffles.

Tissue details (datasheet): In adult kidney, expressed on the urinary surface and foot processes of podocytes and in parietal epithelial cells of Bowman's capsule where it is localized to luminal surfaces. In lung, expressed exclusively on luminal surfaces of type I alveolar epithelial cells and pleural mesothelial cells. Not expressed in type II alveolar cells. In bone, expressed in osteocytes and osteoblasts. In spleen, liver, stomach and intestine, expressed in mesoepithelium. Also expressed in thymic epithelial cells, choroid plexus and leptomeninges. .

Sequence similarities (datasheet): Belongs to the heparin-binding growth factors family.

Research relevance and current trends

• Commonly studied in contexts related to Vasculature.
• Supports comparative expression analysis across conditions, genotypes, or treatments when paired with appropriate controls.
• Useful for confirming target presence and subcellular distribution using orthogonal readouts (e.g., microscopy vs. immunoblotting).

Common research applications

• Western blot (WB): Compare relative target abundance and apparent size/isoforms across samples; interpret bands in light of expected MW and potential PTMs.
• ELISA: Measure target abundance in compatible matrices using a standard-curve readout; ensure dilution linearity and appropriate controls.
• Immunohistochemistry (IHC): Assess tissue distribution and cell-type patterns; interpret staining with appropriate negative controls and antigen context.
• Flow cytometry: Quantify target-positive populations in single-cell suspensions; pair with viability and isotype/FMO controls conceptually.

Notes for experimental interpretation

• Consider isoforms, post-translational modifications, and processing that can shift apparent molecular weight or localization.
• Cross-reactivity (datasheet): No cross-reactivity with other proteins
• Use appropriate positive and negative controls (e.g., KO/KD, blocking peptide, or isotype controls) to support specificity interpretation.

As a polyclonal antibody, this reagent may recognize multiple epitopes on the target, which can improve detection robustness but may require careful specificity controls.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.